Abhay K Kattepur1, Shraddha Patkar2, Mahesh Goel1, Anant Ramaswamy3, Vikas Ostwal3. 1. Gastrointestinal Oncology services, Department of Surgical Oncology, Tata Memorial Hospital, Dr. E. Borges Marg, Parel, Mumbai, 400012, India. 2. Gastrointestinal Oncology services, Department of Surgical Oncology, Tata Memorial Hospital, Dr. E. Borges Marg, Parel, Mumbai, 400012, India. drshraddhapatkar@gmail.com. 3. Gastrointestinal Oncology services, Department of Medical Oncology, Tata Memorial Hospital, Dr. E. Borges Marg, Parel, Mumbai, 400012, India.
Abstract
BACKGROUND: Management of operable gall bladder cancer (GBC) is closely related to its tumor (T) and nodal (N) status. The magnitude of benefit with adjuvant chemotherapy in completely resected, node negative T2 cancers is not completely defined. MATERIALS AND METHODS: Retrospective analysis of patients diagnosed with pathological T2N0 (stage II, 7th edition AJCC) GBCs from January 2011 to June 2016 was evaluated for adverse risk factors, adjuvant treatment received, recurrence-free survival (RFS), and overall survival (OS). Survival analysis was done using Kaplan-Meier and Cox regression tools. RESULTS: Of the 88 patients included, 30 received adjuvant chemotherapy while 58 were observed. The OS and RFS in the entire cohort were 82.9% and 62.7%, respectively, at a median follow-up of 44.18 months. The OS and RFS in the chemotherapy group were 85.1% and 76.4% while it was 81.4% and 55.5% in the observation group (p = 0.50). Recurrent disease was seen in 30.7%.The presence of lymphovascular invasion predicted inferior RFS (p = 0.031). CONCLUSIONS: Adjuvant chemotherapy may reduce distant failure rates but did not improve OS in completely resected T2N0 GBC patients in this study. LVI predicted inferior RFS in T2N0 patients. An evaluation of adverse prognostic factors would help design personalized treatment strategies for this select cohort of T2N0 GBC.
BACKGROUND: Management of operable gall bladder cancer (GBC) is closely related to its tumor (T) and nodal (N) status. The magnitude of benefit with adjuvant chemotherapy in completely resected, node negative T2 cancers is not completely defined. MATERIALS AND METHODS: Retrospective analysis of patients diagnosed with pathological T2N0 (stage II, 7th edition AJCC) GBCs from January 2011 to June 2016 was evaluated for adverse risk factors, adjuvant treatment received, recurrence-free survival (RFS), and overall survival (OS). Survival analysis was done using Kaplan-Meier and Cox regression tools. RESULTS: Of the 88 patients included, 30 received adjuvant chemotherapy while 58 were observed. The OS and RFS in the entire cohort were 82.9% and 62.7%, respectively, at a median follow-up of 44.18 months. The OS and RFS in the chemotherapy group were 85.1% and 76.4% while it was 81.4% and 55.5% in the observation group (p = 0.50). Recurrent disease was seen in 30.7%.The presence of lymphovascular invasion predicted inferior RFS (p = 0.031). CONCLUSIONS: Adjuvant chemotherapy may reduce distant failure rates but did not improve OS in completely resected T2N0 GBC patients in this study. LVI predicted inferior RFS in T2N0 patients. An evaluation of adverse prognostic factors would help design personalized treatment strategies for this select cohort of T2N0 GBC.
Entities:
Keywords:
Adjuvant chemotherapy; Gall bladder cancer; Lymphovascular invasion (LVI); T2N0
Authors: Samuel J Wang; Andrew Lemieux; Jayashree Kalpathy-Cramer; Celine B Ord; Gary V Walker; C David Fuller; Jong-Sung Kim; Charles R Thomas Journal: J Clin Oncol Date: 2011-11-07 Impact factor: 44.544
Authors: Thomas A Aloia; Nicolas Járufe; Milind Javle; Shishir K Maithel; Juan C Roa; Volkan Adsay; Felipe J F Coimbra; William R Jarnagin Journal: HPB (Oxford) Date: 2015-08 Impact factor: 3.647
Authors: Gyulnara G Kasumova; Omidreza Tabatabaie; Robert M Najarian; Mark P Callery; Sing Chau Ng; Andrea J Bullock; Robert A Fisher; Jennifer F Tseng Journal: Ann Surg Date: 2017-10 Impact factor: 12.969
Authors: Mairead G McNamara; Thomas Walter; Anne M Horgan; Eitan Amir; Sean Cleary; Elizabeth L McKeever; Trisha Min; Elaine Wallace; David Hedley; Monika Krzyzanowska; Malcolm Moore; Steven Gallinger; Paul Greig; Stefano Serra; Laura A Dawson; Jennifer J Knox Journal: Am J Clin Oncol Date: 2015-08 Impact factor: 2.339
Authors: Alexander R Siebenhüner; Heike Seifert; Helga Bachmann; Burkhardt Seifert; Thomas Winder; Jonas Feilchenfeldt; Stefan Breitenstein; Pierre-Alain Clavien; Roger Stupp; Alexander Knuth; Bernhard Pestalozzi; Panagiotis Samaras Journal: BMC Cancer Date: 2018-01-11 Impact factor: 4.430